Premium
Class II radical hysterectomy for stage I–IIA cervix cancer: Prognostic factors associated to recurrence and survival in a northeast Brazil experience
Author(s) -
Bezerra Artur Lício Rocha,
Martins Mário Rino,
Bezerra Simone Maria Muniz da Silva,
Figueiroa José Natal,
Batista Thales Paulo
Publication year - 2011
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21939
Subject(s) - medicine , radical hysterectomy , cervix , hysterectomy , stage (stratigraphy) , gynecology , cervical cancer , cancer , oncology , surgery , paleontology , biology
Background The main aim of this study was describe the author's experience with class II radical hysterectomy and pelvic lymphadenectomy to treat stage I–IIA cervix cancer and reexamine some prognostic factors associated with disease recurrence and patient survival in this data from northeast Brazil. Methods A cross‐sectional study was carried out on patients treated at our Centers from January 2001 to December 2008. Statistical analyses were performed using conventional methods. Results Eighty‐eight patients were selected to analysis. Over the 7.3‐year follow‐up, 80 (91%) patients were alive and 8 (9%) disease recurrences were observed. Overall 1‐, 2‐, and 5‐year patients survival was 96.5%, 95.3%, and 84%, respectively. Recurrence was associated to tumor size ≥1 cm ( P = 0.021) and compromised vaginal margin ( P = 0.020). Lower survivals were associated to tumor size ≥1 cm ( P = 0.038), compromised vaginal margin ( P < 0.001), and lymph node metastasis ( P = 0.024). Postoperative complications (n = 11) included wound infection (5.7%), partial wound dehiscence (3.4%), and bladder atony (3.4%). Conclusions Class II radical hysterectomy has provided appropriated disease control of cervix cancer with low morbidity in our experience. Furthermore, tumor size and compromised vaginal margin were significantly associated to recurrence. These factors and lymph node metastasis were also associated to lower 5‐year survival according to our analysis. J. Surg. Oncol. 2011; 104:255–259. © 2011 Wiley‐Liss, Inc.